PURPOSE: To identify cystoid macular edema (CME) in patients with retinitis pigmentosa (RP) using optical coherence tomography (OCT) and to evaluate response to acetazolamide by serial OCT. METHODS: Twenty-nine consecutive RP patients were included in the study. Patients with CME were treated with acetazolamide (125 or 250 mg/d for 4-12 months). OCT, fluorescein angiography, and determination of best-corrected visual acuity (BCVA) were performed initially and throughout the follow-up period. RESULTS: Ten of the 29 patients had CME by OCT. Of these 10 patients, 5 had various degrees of fluorescein leakage by fluorescein angiography. After acetazolamide treatment, six patients had significant decreases in macular edema in at least one eye by follow-up OCT. In six patients, visual acuity improved by > or =1 line in at least one eye. The change of central foveal thickness shown by OCT was significantly correlated with the change of logMAR of BCVA (Pearson correlation coefficient [r] = 0.576; P = 0.008). We observed no differences in the change of central foveal thickness by OCT (Mann-Whitney test; P = 1.000) and in the change of logMAR of BCVA (Mann-Whitney test; P = 0.106) between patients treated with 125 mg/d acetazolamide and those treated with 250 mg/d acetazolamide. CONCLUSIONS: These results indicate that OCT is a valuable tool in the detection and follow-up of CME in RP patients. Treatment with acetazolamide resulted in marked improvement in OCT-diagnosed CME in RP, but visual improvement was variable.
PURPOSE: To identify cystoid macular edema (CME) in patients with retinitis pigmentosa (RP) using optical coherence tomography (OCT) and to evaluate response to acetazolamide by serial OCT. METHODS: Twenty-nine consecutive RP patients were included in the study. Patients with CME were treated with acetazolamide (125 or 250 mg/d for 4-12 months). OCT, fluorescein angiography, and determination of best-corrected visual acuity (BCVA) were performed initially and throughout the follow-up period. RESULTS: Ten of the 29 patients had CME by OCT. Of these 10 patients, 5 had various degrees of fluorescein leakage by fluorescein angiography. After acetazolamide treatment, six patients had significant decreases in macular edema in at least one eye by follow-up OCT. In six patients, visual acuity improved by > or =1 line in at least one eye. The change of central foveal thickness shown by OCT was significantly correlated with the change of logMAR of BCVA (Pearson correlation coefficient [r] = 0.576; P = 0.008). We observed no differences in the change of central foveal thickness by OCT (Mann-Whitney test; P = 1.000) and in the change of logMAR of BCVA (Mann-Whitney test; P = 0.106) between patients treated with 125 mg/d acetazolamide and those treated with 250 mg/d acetazolamide. CONCLUSIONS: These results indicate that OCT is a valuable tool in the detection and follow-up of CME in RP patients. Treatment with acetazolamide resulted in marked improvement in OCT-diagnosed CME in RP, but visual improvement was variable.
Authors: Michael A Sandberg; Robert J Brockhurst; Alexander R Gaudio; Eliot L Berson Journal: Invest Ophthalmol Vis Sci Date: 2008-06-14 Impact factor: 4.799
Authors: Ian R Gorovoy; Denise S Gallagher; Andrew W Eller; Vera A Mayercik; Thomas R Friberg; Joel S Schuman Journal: Semin Ophthalmol Date: 2013-03 Impact factor: 1.975
Authors: Michael A Sandberg; Elizabeth N Pearce; Shyana Harper; Carol Weigel-DiFranco; Lois Hart; Bernard Rosner; Eliot L Berson Journal: JAMA Ophthalmol Date: 2014-10 Impact factor: 7.389
Authors: Judith Mosinger Ogilvie; Kevin K Ohlemiller; Gul N Shah; Barbara Ulmasov; Timothy A Becker; Abdul Waheed; Anne K Hennig; Peter D Lukasiewicz; William S Sly Journal: Proc Natl Acad Sci U S A Date: 2007-05-07 Impact factor: 11.205
Authors: Elena Pacella; Loredana Arrico; Valentina Santamaria; Paolo Turchetti; Maria Rosaria Carbotti; Giuseppe La Torre; Fernanda Pacella Journal: Ophthalmol Eye Dis Date: 2014-05-27